MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is making strides in workplace safety with its AI-powered voice analysis platform designed to detect drug and alcohol impairment in real time. The technology, trained on over 50 million data points and analyzing more than 140 acoustic markers, offers a non-invasive alternative to traditional testing methods such as breath, saliva, urine, and laboratory-based tests. According to the company, the platform can deliver impairment assessments from short speech samples, using Edge AI kiosks that process voice data locally for rapid results.
The initial commercial focus is on South American mining operations, where large-scale workforce screening presents significant safety and logistical challenges. Field testing is planned to begin in 2026. Beyond mining, MindBio sees opportunities to expand into aviation, construction, transportation, law enforcement, call centers, and healthcare. The global alcohol and drug testing devices market is projected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033, according to industry forecasts, driving demand for faster, scalable solutions.
MindBio's platform leverages proprietary research in voice analysis and artificial intelligence to predict intoxication levels. The company is developing an enterprise platform that includes Edge-AI kiosks integrating bespoke hardware and software for detection in various environments. For more details, view the full article at https://ibn.fm/Gw5Fa. Latest news and updates relating to MBQIF are available in the company's newsroom at https://ibn.fm/MBQIF.
